This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ISAR-REACT 5 was a phase 4 randomized parallel-group trial evaluating ticagrelor versus prasugrel in patients with acute coronary syndrome.
| Feature | ISAR-REACT 5 |
|---|---|
| NCT ID | NCT01944800 |
| Phase | Phase 4 |
| Status | COMPLETED |
| Condition | Acute Coronary Syndrome (ACS) |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | SINGLE |
| Primary purpose | TREATMENT |
2. Clinical Question
Population
Patients with acute coronary syndrome.
Intervention
Ticagrelor.
Comparator
Prasugrel.
Primary question
The registry evaluated the comparison of ticagrelor versus prasugrel for the composite endpoint of death, myocardial infarction or stroke at 12 months.
3. Trial Design
Randomization
Randomized assignment.
Structure
Parallel-group design with two treatment arms.
Sponsor
Deutsches Herzzentrum Muenchen.
Sponsor type
OTHER.
4. Planned Endpoint Analysis
The ClinicalTrials.gov record lists the primary endpoint as:
| Endpoint | Time frame |
|---|---|
| Composite of death, myocardial infarction or stroke | 12 months |
The endpoint is a composite time-based clinical outcome. A typical statistical analysis for this type of randomized trial would compare event occurrence between treatment groups using methods appropriate for binary or time-to-event outcomes, depending on the prespecified statistical analysis plan. The registry does not report posted statistical analyses or endpoint results.
5. Statistical Methodology
Composite endpoints
A composite endpoint combines multiple clinical events into a single outcome measure. This can increase statistical efficiency because more events contribute to the analysis, but interpretation depends on the clinical importance and frequency of each component.
When interpreting a composite outcome, the overall result represents the combined endpoint rather than automatically demonstrating identical effects across each individual component.
Randomized treatment comparison
Randomization is designed to balance measured and unmeasured factors between treatment groups on average, allowing differences in outcomes to be attributed to treatment assignment under the assumptions of the trial design.
Missing data and censoring
The registry does not report missing-data handling, censoring rules, interim analyses, multiplicity procedures, Bayesian methods, or stratification methods.
6. Statistical Methods Explained
Why use a composite endpoint?
A composite endpoint can provide more observed events than a single component endpoint. However, the interpretation depends on the contribution of each component to the overall result.
Why does randomization matter?
Randomization creates the comparison framework that supports causal interpretation by reducing systematic differences between assigned treatment groups.
How would a 12-month composite endpoint typically be analyzed?
Analysis depends on the prespecified statistical plan. Common approaches include comparing event proportions or modeling time to first occurrence of the composite event.
Why are individual components important?
A composite endpoint may contain events with different clinical importance or frequency, so component-level interpretation is important when results are available.
What does the absence of posted analyses mean?
The registry reports the endpoint definition but does not report formal statistical analyses or results for the endpoint.
7. Planned Analysis
The registry states that the primary endpoint is the composite of death, myocardial infarction or stroke at 12 months. Results have not been posted on ClinicalTrials.gov.
8. Limitations
- The ClinicalTrials.gov record does not report endpoint estimates, confidence intervals, p-values, or posted statistical analyses.
- Baseline characteristics and subgroup analyses are not reported in the registry record.
- Details of missing-data handling, multiplicity control, and interim monitoring are not reported.
- Without posted analyses, the statistical interpretation is limited to the registered design and endpoint framework.
9. Why This Trial Matters Statistically
| Concept | How it appears in ISAR-REACT 5 |
|---|---|
| Randomization | Randomized comparison of two interventions. |
| Parallel design | Two-arm parallel treatment structure. |
| Composite endpoint | Death, myocardial infarction or stroke. |
| Time frame | Primary endpoint assessed at 12 months. |